期刊
BIOENGINEERING & TRANSLATIONAL MEDICINE
卷 3, 期 2, 页码 75-86出版社
WILEY
DOI: 10.1002/btm2.10097
关键词
-
资金
- National Institutes of Health [DP5OD012133]
- UC CAI [U54HL119893]
- UCLA CTSI [UL1TR001881]
- NIH [F30CA183528]
- NIH Biotechnology Training in Biomedical Sciences and Engineering Program [T32 GM067555]
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-beta) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant. However, clinical translation of TGF-beta CAR-T cells for cancer therapy requires the ability to productively combine TGF-beta responsiveness with tumor-targeting specificity. Furthermore, the potential concern that contaminating, TGF-beta-producing regulatory T (Treg) cells may preferentially expand during TGF-beta CAR-T cell manufacturing and suppress effector T (Teff) cells demands careful evaluation. Here, we demonstrate that TGF-beta CAR-T cells significantly improve the anti-tumor efficacy of neighboring cytotoxic T cells. Furthermore, the introduction of TGF-beta CARs into mixed T-cell populations does not result in the preferential expansion of Treg cells, nor do TGF-beta CAR-Treg cells cause CAR-mediated suppression of Teff cells. These results support the utility of incorporating TGF-beta CARs in the development of adoptive T-cell therapy for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据